Abstract:
PURPOSE: A biomarker for diagnosing cardiac arrhythmia is provided to determine cardiac arrhythmia from a biological sample and to identify mechanisms of cardiac arrhythmia. CONSTITUTION: A biomarker for diagnosing cardiac arrhythmia contains one or more proteins selected among: ATP synthase D chain, mitochondrial with an amino acid of sequence number 1; a proteasome beta 4 subunit with an amino acid of sequence number 2; myosin light chain 2 with an amino acid of sequence number 3; peripherin with an amino acid of sequence number 4; glutaredoxin 3 with an amino acid of sequence number 5; cytochrome b-c1 complex subunit 1 with an amino acid of sequence number 6; and Nogo-A with an amino acid of sequence number 7. The expression of the biomarker is relatively increased in cardiac muscle cells of cardiac arrhythmia comparing with the expression in normal cardiac muscle cells.
Abstract:
본 발명은 세포 내 STAT1의 인산화 수준을 측정하는 방법에 관한 것으로서, 더욱 상세하게는 인산화된 STAT1을 인식하는 항체와 FITC가 결합된 2차 항체를 이용하여 사이토카인에 의해 자극된 세포에서 STAT1의 인산화 정도를 신속하게 측정하기 위한 세포 내 STAT1의 인산화 수준을 측정하는 방법에 관한 것이다. 이러한 본 발명의 세포 내 STAT1의 인산화 수준 측정 방법은 사이토카인에 의해 자극된 세포에서 STAT1 단백질의 인산화 정도와의 상대적 비교를 통하여 측정하고자 하는 세포의 인산화 수준을 신속하고 정밀하게 측정 가능하여 STAT1 이외의 다른 단백질들의 분석에도 적용 가능하고, 약물 개발 등에 유용하리라 기대된다.
Abstract:
A method for measuring activation levels of kinase in cells is provided to reduce the measuring costs, and improve measuring accuracy and rapidness by using capillary tube electrophoresis. The method for measuring activation levels of kinase in cells comprises the steps of: (1) treating the cells to be measured with cytokine; (2) adding a cell dissolving buffer solution containing beta-glycerophosphate, EGTA(ethylene glycol bis(b-aminoethylether) tetraacetic acid), EDTA(ethylenediamine tetraacetic acid), Na3VO4, DTT(dithiothreitol) and protein inhibitor into the cells; (3) centrifuging the cells to obtain the cell extract; (4) combining the cell extract with kinase(Akt) and ATP-Mg mixture; (5) reacting the mixture in kinase buffer at 25-35 deg. C for 10-30 minutes; (6) separating the resulting products into a substrate and reaction product by using UV-capillary tube electrophoresis; and (7) quantitavely measuring the separated substrate and reaction products, wherein the Akt substrate has the amino acid sequence of SEQ ID NO:1.
Abstract translation:提供了一种测量细胞中激酶活化水平的方法,以减少测量成本,并通过使用毛细管电泳提高测量的准确性和快速性。 测定细胞激酶水平的方法包括以下步骤:(1)用细胞因子处理待测细胞; (2)向细胞中加入含有β-甘油磷酸酯,EGTA(乙二醇双(b-氨基乙醚)四乙酸),EDTA(乙二胺四乙酸),Na 3 VO 4,DTT(二硫苏糖醇)和蛋白质抑制剂的细胞溶解缓冲溶液; (3)离心细胞获得细胞提取物; (4)将细胞提取物与激酶(Akt)和ATP-Mg混合物组合; (5)使该混合物在25-35℃的激酶缓冲液中反应。 C 10-30分钟; (6)使用紫外 - 毛细管电泳将得到的产物分离成底物和反应产物; 和(7)定量测量分离的底物和反应产物,其中Akt底物具有SEQ ID NO:1的氨基酸序列。
Abstract:
The present invention relates to an siRNA for inhibiting expression of OTUB1 protein and a composition comprising the same as an active ingredient for preventing or treating cancer. According to the present invention, the siRNA of the present invention can remarkably inhibit growth of cancer cells by inhibiting expression of the OTUB1 protein.
Abstract:
PURPOSE: A method for detecting NFAT which is a biomarker for myocardial hypertrophy, using a capillary electrophoretic mobility shift assay by DNA binding is provided to effectively determine myocardial hypertrophy and to identify myocardial hypertrophy mechanism. CONSTITUTION: A method for detecting NFAT which is a biomarker for myocardial hypertrophy comprises: a step of reacting a quantitated nuclear extract and a fluorescent residue-labeled DNA in a buffer solution; a step of detecting DNA-conjugated NFAT using laser-induced fluorescence and isolating by capillary electrophoresis; and a step of quantitating detected activated T cell nuclear factor(NFAT) and a product thereof. The fluorescent residue-labeled DNA contains a probe with 5'-CAGCTAGGAAACAATTGGAAGTG-3' sequence. The probe specifically binds to NFAT.
Abstract:
PURPOSE: A biomarker for myocardial hypertrophy diagnosis and a myocardial hypertrophy diagnosis method using the same are provided to judge myocardial hypertrophy from the biological material. CONSTITUTION: A biomarker for myocardial hypertrophy diagnosis comprises PDZ and LIM domain protein which have amino acid sequence described in sequence number 1(SEQ ID NO:1), ADP-ribosyl hydrolase which has amino acid sequence described in sequence number 2, peptidyl - prolyl cis-trans isomerase E which has amino acid sequence described in sequence number 3, translation extension element 1 delta isoform b of eukaryotic cells which has amino acid sequence described in sequence number 4, Ran- specific GTPase- activator protein which has amino acid sequence described in sequence number 5, ATP synthase subunit beta which has amino acid sequence described in sequence number 6, mitochondrial precursor, or isoform 1 of astrocytic phosphor protein PEA-15 which has amino acid sequence described in sequence number 7.
Abstract:
본 발명은 세포 내 STAT1의 인산화 수준을 측정하는 방법에 관한 것으로서, 더욱 상세하게는 인산화된 STAT1을 인식하는 항체와 FITC가 결합된 2차 항체를 이용하여 사이토카인에 의해 자극된 세포에서 STAT1의 인산화 정도를 신속하게 측정하기 위한 세포 내 STAT1의 인산화 수준을 측정하는 방법에 관한 것이다. 이러한 본 발명의 세포 내 STAT1의 인산화 수준 측정 방법은 사이토카인에 의해 자극된 세포에서 STAT1 단백질의 인산화 정도와의 상대적 비교를 통하여 측정하고자 하는 세포의 인산화 수준을 신속하고 정밀하게 측정 가능하여 STAT1 이외의 다른 단백질들의 분석에도 적용 가능하고, 약물 개발 등에 유용하리라 기대된다.